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A new abnormal hemoglobin was found in a diabetic Maltese woman by citrate agar electrophoresis. This 
variant was undetectable by isoelectric focusing. No hematological abnormalities were observed. The struc- 
tural analysis included isolation of the abnormal b chain, high pressure liquid chromatography of the cor- 
responding tryptic peptides and then microsequencing of the abnormal T,. These procedures revealed a dou- 
ble abnormality: the presence of a methionyl residue extending the NH, terminus and a histidine to proline 
substitution in position NA,. 
Hemoglobinopathy /I variant HPLC 
1. INTRODUCTION 
An increasing number of hemoglobin variants 
are detected in the course of Hb AI, evaluation in 
diabetic patients [ 1,2]. Here we detected a 
hemoglobin fraction behaving like Hb F or Hb A,, 
by citrate agar electrophoresis (Corning Medical, 
USA) in a 64-year-old woman with mild diabetes. 
She was of Maltese origin but lived in Marseille. 
Structural studies allowed the observation of a 
very unusual modification, since, together with a 
His to Pro substitution at the NA2 position, we 
have demonstrated the persistence of the initiating 
methionine. This illustrates that structural studies 
of hemoglobin variants can still provide some in- 
sight into molecular mechanisms. 
2. MATERIALS AND METHODS 
Standard hematological procedures were fol- 
lowed. Heinz bodies staining was performed with 
Cresyl brilliant blue (1 vo) after 3 h sterile incuba- 
tion at 37°C. Freshly prepared hemolysates were 
subjected to the 4 classical electrophoretic systems 
+ To whom correspondence should be addressed 
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as proposed in [3]. Electrophoresis at alkaline pH 
(Tris-EDTA-borate buffer) was performed on 
cellulose acetate strips (Helena Titan III H), citrate 
agar electrophoresis (pH 6.2) on plates from 
Helena (Titan IV), and globin chain elec- 
trophoresis in 6 M urea, 1% &mercaptoethanol 
(pH 6 and 9) on cellulose acetate strips 
(Sepraphore X Gelman). Isoelectric focusing (IEF) 
was carried out on a thin-layer polyacrylamide gel 
(pH 6-9) as in [4]. Globin chain analysis on 
acid-urea-Triton acrylamide gel was performed 
as in [5]. Densitometry of acid-urea-Triton 
polyacrylamide slabs was done with a Cellosystem 
Sebia densitometer (France). Quantification of Hb 
F was as in [6] and the A2 level was measured 
chromatographically as in [7]. Stability was tested 
by the isopropanol test as in [8]. The 
methemoglobin fraction in the fresh hemolysate 
was spectrophotometrically evaluated with a Cary 
118 C instrument. The oxygen affinity of the 
whole blood was determined with an Aminco 
Hemoscan (Silver Springs, USA) and the 2,3-DPG 
assay was performed as in [9]. The abnormal 
hemoglobin was separated by Biorex 70 
chromatography according to [lo] with some 
modifications [ 1 l] (fig. 1). Purity of the abnormal 
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hemoglobin was assessed by citrate agar elec- 
trophoresis and by acid-urea-Triton polyacryl- 
amide gel electrophoresis (fig. 1). The abnormal 
P chain after desheminisation by acid-acetone pre- 
cipitation was prepared by CM-cellulose 8 M 
urea chromatography [ 121, aminoethylated and 
stripped of urea on a Biogel P2 (Biorad) column 
and hydrolysed with trypsin. Two methods were 
used for the characterization of tryptic peptides: (i) 
fingerprinting on silica gel thin-layer plates [13] 
and specific staining for histidine, tyrosine, tryp- 
tophan, arginine and methionine [14]; (ii) HPLC 
using a Beckman model 343 with an Altex wave- 
length detector set at 214 nm. The column system 
was a Waters PBondapack Cl8 (lOpm, ID 
3.9 mm, 30 cm). The solvent system was based on 
[15]: solvent A, 0.02 M ammonium acetate (pH 
5.7); solvent B, 0.01 M ammonium acetate (pH 
5.7) mixed 50/50 with acetonitrile (Baker, v/v). 
The gradient was linear from 0 to 60% in 50 min 
and from 60 to 100% in 10 min. Amino acid com- 
position was determined on a Biotronik 6000 IE 
(Biotronik, Munich) after 40 h hydrochloric acid 
hydrolysis of separated peptides. The abnormal 
peptide (Tl) was in parallel subjected to the 
microsequencing procedure according to [ 161. 
3. RESULTS 
3.1. Case report 
The propositus and one of her nieces were found 
to carry the fl globin variant trait. Hematological 
data for both were in the normal range. The 
following data concern only the propositus. The 
abnormal Hb component constituted 44% of the 
total p chains as evaluated by densitometry of an 
acid-urea-Triton polyacrylamide gel elec- 
trophoresis (fig.2, lane 2). Hb AZ was 2.6% (N = 
2 - 3.1) and Hb F 0.45% (N < 1). No Heinz 
bodies were seen after 3 h incubation with Brilliant 
Cresyl blue. The isopropanol test was negative. 
The PsO of whole fresh blood was 27 mmHg (N = 
25 - 29). 2,3-DPG was 14.55 PM/g Hb (N = 13 
- 15). The level of ferrihemoglobin in the fresh 
hemolysate was below 1%. Electrophoretic 
mobilities according to [3] were, respectively: 
cellulose acetate electrophoresis (pH 8.7), 0.0; 
citrate agar (pH 6.2), -4.4; globin chain elec- 
trophoresis (pH 9.0 and 6.0), 20.0 and 21.7. 
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Fig.1. Biorex 70 chromatographic pattern of the 
propositus hemolysate. Peak I, Hb Ao; peak II, Hb 
Marseille; peak III, NHP (non-heme proteins), and 
minor fast hemoglobin derivatives. 300 mg hemolysates; 
column, 4 2.5 x 20 cm; Biorex 70 (200-400 mesh), pH 
6.75; phosphate (NaHzP04) buffer, 0.048 M; NaCl, 
linear gradient, 0 -+ 0.3 M. 
Mobility in acid-urea-Triton polyacrylamide gel 
electrophoresis was 23.1; isoelectric focusing, no 
separation. 
3.2. Structural studies 
Fig.1 shows the elution profile of the abnormal 
hemoglobin after Biorex 70 chromatography and 
fig.2 the acid-urea-Triton polyacrylamide elec- 
trophoretic pattern of the successive peaks I and 
II. The data obtained indicated that peak II was 
composed of the abnormal Hb fraction and was 
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Fig.2. Acid-urea-Triton polyacrylamide gel electro- 
phoretic analysis of the hemoglobin composition in the 
peaks (I and II) obtained by Biorex 70 chromatography 
compared to a control and to the whole hemolysate. 
Lanes: (1) peak II; (2) whole hemolysate; (3) Hb Ao; (4) 
cord blood sample (with a Hb LY variant). 
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slightly (less than 10%) contaminated by the 
glycosylated form of tHb AO as shown in fig.2 (6’ 
A1, has the same mobility as fl AO in this elec- 
trophoretic system). Peak III was mainly com- 
posed of non-heme proteins (NHP) and some 
minor fast Hb derivatives. Peak I was Hb Ao. 
Structural studies were conducted using the ab- 
normal hemoglobin component present in peak II. 
Tryptic peptides of the ,8 abnormal chain were first 
studied by fingerprinting. The T1 is absent and a 
new spot of higher chromatographic mobility and 
more anodic was seen. Specific stainings revealed 
besides an otherwise normal pattern for the other 
spots, a negative histidine and a positive 
methionine coloration for the atypical spot. 
Secondly, in the HPLC separation of the non- 
aminoethylated tryptic peptides, as shown in fig.3, 
,&Tr was absent and a peak with a longer retention 
time was present. Three successive HPLC steps 
permitted the accumulation of a sufficient amount 
of this peptide to perform amino acid analysis and 
a manual microsequence analysis. The amino acid 
molar ratios (table 1) showed a fl Tr with a 
histidine to proline substitution and an extra 
methionine, besides an otherwise normal amino 
acid composition. Five steps of microsequencing 
procedure performed on this abnormal peptide 
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Fig.3. HPLC elution pattern of the non-aminoethylated 
tryptic peptides of the Hb Marseiile fi chain. Arrow, 
abnormal ,&Tr; dotted line, elution position of normal 
PTI. 
Table 1 
Amino acid composition of PTI of Hb Marseille 
compared to normal fit 
,#T I expected fl Marseille Tr 
AA molar ratio observed 
AA molar ratio 
Thr 
Glu (Gln) 
Pro 
Val 
Met 
Leu 
His 
LYS 
1 0.90 
2 1.90 
1 1.80 
1 1.00 
0 0.80 
1 1.00 
1 0.00 
1 0.90 
revealed the following sequence: Met ---+ Val --+ 
Pro ---+ Leu - Thr. 
4. DISCUSSION 
Hb Marseille has some unusual biochemical 
features. One of the structural abnormalities in- 
volves the substitution of the histidine NAz by a 
proline. This modification is homologous to that 
described in Hb Deer Lodge ,6 (NAz) His - Arg 
[17] and OkayamaP (NA2) His ---+ Gln 1181. 
The electrophoretic behaviour of Hb Marseille 
deserves some comment. Citrate agar elec- 
trophoresis is known to explore, in part, the dif- 
ferences in the electropositivity of the central cavi- 
ty of Hb variants [19,20]. In this system, like Hb 
Al, and Hb Raleigh fl (NAI) Val ---+ AC Ala [21], 
Hb Marseille, in which the histidine NA2 is 
substituted by a neutral residue, has a higher 
mobility. The separation of Hb Marseille, like Hb 
Okayama [I81 in Biorex 70 chromatography, is 
sustained by a similar mechanism [lo]. 
The substitution of His (NA2) by Pro probably 
affects negatively the interaction between Hb and 
2,3-DPG. In Hb Marseille the whole blood PSO was 
expected to be lowered as in Hb Deer Lodge 1171 
and Hb Okayama [18]. The finding of a normal 
PSO may indicate a low oxygen affinity of the Hb 
Marseille tetramers in the absence of allosteric ef- 
fectors. Detailed Hb function studies are currently 
underway to provide a full description of the func- 
tional properties of Hb Marseille. 
The finding of a methionine residue at the NH2 
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terminus of the Hb Marseille ,L? chain was firmly 
demonstrated by amino acid analysis, by stainings 
of the fingerprint, and by microsequencing data. 
Furthermore the achievement of the sequence 
analysis procedure showed that the NH2 of the 
methionine was not blocked in, at least, a large 
fraction of Hb Marseille. 
In the absence of data on the patient’s DNA, 
and since we were unable to propose, starting from 
the DNA sequence of the Hb /3 chain [22], a unique 
DNA rearrangement that could produce such a 
modified ,8 chain, we propose that the NH2 ter- 
minal methionine present in Hb Marseille is the in- 
itiating methionine. In this hypothesis the occur- 
rence of a proline in position NAz would constitute 
a steric impairment for the NH2 methionyl pep- 
tidase normally eliminating rapidly the initiating 
methionine [23]. A very similar hypothesis has 
been stated for naturally occurring proteins with a 
met--X NHz-terminal sequence, in which X is 
either a charged amino acid [24,25] or a proline 
[26,27]. 
Thus the NH2 terminus of Hb Marseille ,B chain 
seems to be an inadequate substrate for both N- 
methionyl peptidase and NH2 terminal acetyl 
transferase in contrast to Hb F y chains [28] and 
Hb Raleigh ,L? chains [21]. Finally, the amino acid 
analysis showed that NH2 terminal methionine was 
not in its oxidized form, a result expected after the 
observed neutral electrophoretic behaviour in 
globin chain pH 9.0 electrophoresis. 
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